Clinical Medicine: Oncology
Synopsis: An open access, peer reviewed electronic journal that covers cancer research and treatment.
Indexing: 5 major databases. Pubmed indexing for NIH-funded research.
Processing time: Decision in 2 weeks for 90% of papers.
Visibility: Most popular article read 800+ times.
About this journal
Aims and scope:
Clinical Medicine: Oncology is an international peer reviewed open access journal which publishes articles on all aspects of cancer research and treatment. Of particular interest are the following topics:- Molecular biology
- Genetics
- Pathophysiology
- Epidemiology
- Clinical interventions
- Controlled trials
- The diagnosis and treatment of patients with cancer
- Therapeutics, pharmacology and drug delivery
- Techniques of cancer surgery
Editorial standards and procedures:
Submissions, excluding editorials, letters to the editor and dedications, will be peer reviewed by two reviewers. Reviewers are required to provide fair, balanced and constructive reports.
Under our Fairness in Peer Review Policy authors may appeal against reviewers' recommendations which are ill-founded, unobjective or unfair. Appeals are considered by the Editor in Chief or Associate Editor.
Papers are not sent to peer reviewers following submission of a revised manuscript. Editorial decisions on re-submitted papers are based on the author's response to the initial peer review report.
Indexing:
This journal is indexed by the following services:
- Google Scholar
- CAS
- DOAJ
- SCOPUS
- OAIster
SPARC Europe Seal award winner:
This journal has been awarded a SPARC Europe Seal. The Seal is an initiative of SPARC Europe (Scholarly Publishing and Academic Resources Coalition) and the Directory of Open Access Journals (DOAJ) which is awarded to journals applying a Creative Commons CC-BY copyright license and that make journal metadata accessible to DOAJ.
Amongst other important services DOAJ makes metadata OAI-compliant. This in turn enhances the visibility of papers and allows OAI-harvesters to include the details of journal articles in their services. We encourage readers to make use of this valuable resource. The DOAJ search page is available here.
National Institutes of Health Public Access Policy compliant:
As of April 7 2008, the US NIH Public Access Policy requires that all peer reviewed articles resulting from research carried out with NIH funding be deposited in the Pubmed Central archive.
If you are an NIH employee or grantee Libertas Academica will ensure that you comply with the policy by depositing your paper at Pubmed Central on your behalf.
Call for papers:
Read the Editor in Chief's latest call for papers here.
Submission types accepted:
- Original research articles.
- Reviews: comprehensive, authoritative, descriptions of any subject within the journal's scope. They may cover basic science and clinical reviews, ethics, pro/con debates, and equipment reviews.
- Commentaries: focused and opinionated articles on any subject within the journal's scope. These articles are usually related to a contemporary issue.
- Hypotheses: articles that present an original hypothesis backed solely by previously published results rather than any new evidence. They should outline significant progress in thinking that would also be testable.
- Letters to the Editor: these can be either a re-analysis of a previously published article, or a response to such a re-analysis from the authors of the original publication.
- Methodology articles: these discuss a new experimental method, test or procedure. The article must describe a demonstrable advance on what is currently available. The method needs to have been well tested and ideally, but not necessarily, used in a way that proves its value.
- Short reports: brief reports of data from original research.
- Meeting reports: a report pertaining to activity at a meeting or conference Articles published in this journal are immediately available without delay upon publication and enjoy substantial visibility.
- Case reports: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association, or present an important adverse reaction. Case reports must meet appropriate ethical standards.
All submissions are subject to prompt, objective and fair peer review in compliance with our Fairness in Peer Review Policy. Copyright in published articles remains with the author(s). Authors are continually informed of the progress of their paper and our staff are friendly and responsive.
One author recently wrote: "I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely."
Criteria for publication:
Publication is dependent on peer reviewers' judgement of papers. Reviewers are asked to provide thoughtful and unbiased feedback to authors to ensure that the conclusions of papers are valid and manuscripts achieve reasonable standards of scholarliness and intelligibility.
Previous work in the field must be acknowledged and papers should read without unreasonable difficulty. Papers should fit comfortably within the scope of the journal.
Reviewers are asked to act in a fair, objective and constructive manner which maintains quality standards and helps authors to communicate their research. They are instructed that in areas of genuinely novel research issues may be raised which cannot immediately be resolved and that absolutely rigorous validation of data may therefore not be possible.
More information on the role of peer reviewers is available on the information for reviewers page. Where authors consider that reviewers have made recommendations which are unreasonable, unobjective or ill-founded they may appeal them to the Editor in Chief or Associate Editor under our Fairness in Peer Review Policy.
Articles submitted to other journals:
We are willing to consider papers which have been peer reviewed by other journals but not accepted for publication.
Services for authors:
Prior to peer review of your paper we can:
- Have your paper's reference style revised to meet our requirements,
- Have your paper's English revised by specialist English-speaking technical editors.
After peer review of your paper we can:
- Have your paper revised in accordance with peer reviewer's recommendations and have a summary of responses to the reviewers created by our specialist external substantive editors,
- Provide bound reprints of your article in colour or black and white ,
- Provide online-early rapid publication if your paper prior to typesetting.
What other authors have said:
Libertas Academica actively requests, receives and acts upon feedback from authors, readers and editorial boards. Here's what some recent authors have said about us:
"Within a couple of days the reviewers had been procured and the manuscript was out."
"The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I've never had such complete communication with a journal."
"LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought."
Article processing fees:
All submissions to this journal are subject to an article processing fee if they are accepted for publication. Article processing fees are used to fund the processing of your paper and development of the journal. Article processing fees are the only compulsory charge you will face and do not vary according to word count, page count, colour figures or any other factor. There is no additional charge for the author(s) to make any use of their article and no charge to readers to access it.
Full fee waivers are available for authors working in undeveloped nations and partial discounts of 20-50% are available to authors in other nations. Authors must be able to verifiably demonstrate their suitability for a discount or waiver. Availability of waivers and discounts is subject to monthly availability and is given at the publisher's discretion. Waivers and discounts must be applied for prior to submission. Neither are available after submission.
Register as a peer reviewer:
Do you wish to register as a peer reviewer? Or are you already a registered peer reviewer but you need to update your contact details? To register or update your details visit the peer reviewer registration form.
Applicants must be able to demonstrate at least five years of continuous experience in the journal's subject area including at least two in the previous 24 months.
Read the Editor in Chief's latest call for papers here.
Journal newsletter sent to subscribers in week 31, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 30, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 25, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 19, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 18, 2009. Register to receive future newsletters.
Follow this journal on Twitter
Journal newsletter sent to subscribers in week 16, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 13, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 10, 2009. Register to receive future newsletters.
New call for papers sent to newsletter subscribers in week 7 2009. Readers who wish to be elligible to receive CFPs should subscribe to the newsletter.
Peer reviewers are sought. Click here to apply or to update your details.
This journal has been accepted for indexing by Elsevier's highly regarded SCOPUS index
Phase II Study of S-1 Monotherapy as a First-line, Combination Therapy of S-1 plus Cisplatin as a Second-line, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma
Yasushi Rino1, Norio Yukawa1, Nobuyuki Wada1, Makoto Suzuki1, Hitoshi Murakami1, Takanobu Yamada1, Hirotaka Nakayama1, Naoto Yamamoto2, Tsutomu Sato2, Roppei Yamada2, Takashi Ohshima2, Munetaka Masuda1, Toshio Imada3
1Department of Surgery, School of Medicine, Yokohama City University; 2Department of Gastroenterological Center, Medical Center, Yokohama City University; 3Hospital of Yokohama City University.
Abstract
Background: We conducted a pilot phase II study to evaluate the efficacy and safety of S-1 as a first-line, S-1 plus cisplatin as a second-line, and weekly paclitaxel as a third-line therapy for advanced gastric cancer.
Patients and methods: Between 2002 and 2005, 19 patients were enrolled in this study. Chemotherapy consisted of either 60 mg/m2 of S-1 for 4 weeks at 6 weeks interval, a combination of 60 mg/m2 S-1 for 3 weeks and 60 mg/m2 cisplatin on day 8 at 5 weeks interval, or 60 mg/m2 paclitaxel at day 1, 8, 15, at 4 weeks interval. The regimen was repeated until the occurrence of unacceptable toxicities, disease progression, or patient refusal. The primary end point was the overall survival.
Results: The response rates were 33.3%, 12.5%, and 0% after the first, second, and third line chemotherapy, respectively. The mean overall survival time was 994 days. The median survival time could not be calculated because 12 out of 19 patients were still alive when the study was concluded. Regarding hematological toxicity, the major adverse effect was leukopenia, which reached grades 3–4 in all lines of chemotherapy investigated. In addition, regarding non-hematological toxicities, the major adverse effect was anorexia, which reached grade 3-4 in the second line chemotherapy, and no deaths were attributable to the adverse effects of the drugs.
Conclusion: This sequential therapy was an effective treatment for advanced gastric cancer with acceptable toxic side-effects. We considered this sequential therapy to be effective because of the smooth switch to the next regimen.
Readers of this also read:
- Octreotide in Palliative Treatment of Hepatic Metastases: Is it Effective for Clinical Stabilization?
- Experimental antioxidant therapy in ataxia telangiectasia
- Multidisciplinary Approach in Managing Orbital Tumors in Ibadan, Nigeria
- Multicentric Adenocarcinomas in a Long-Segment of Barrett’s Esophagus
- Documentation of Complete Response in Metastatic Breast Cancer to Liver and Bone Achieved with Trastuzumab and Pegylated Liposomal Doxorubicin
- 14/Aug/2009
Gastric Adenocarcinoma: Is Computed Tomography (CT) Useful in Preoperative Staging?
- 12/Aug/2009
Genomic Heterogeneity of Breast Tumor Pathogenesis
- 29/Jul/2009
Risk Factors for Renal Cell Cancer in a Japanese Population
- 15/Jun/2009
Treatment of Advanced Non Small Cell Lung Cancer in Routine Care: A Retrospective Analysis of 212 Consecutive Patients Treated in a Community Based Oncology Group Practice
- 01/May/2009
Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results?
- 30/Apr/2009
Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Diagnosis of Recurrent Anal Cancer After Chemoradiation and Negative Forceps Biopsies: A Case Report
- 28/Apr/2009
Glioblastoma Multiforme Oncogenomics and Signaling Pathways
- 08/Apr/2009
Hospital Costs of Colorectal Cancer Care
- 20/Mar/2009
Anticancer Conjugates and Cocktails Based on Methotrexate and Nucleoside Synergism
- 20/Mar/2009
Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone - A Critical Review
- 04/Mar/2009
A Challenging Picture of Cancer-and Inflammation-Related Changes
- 02/Mar/2009
Recurrent Pneumonia Due to an Appendiceal Mucinous Cystadenocarcinoma: A Rare Presentation of a Rare Malignancy
- 02/Mar/2009
Treated Colorectal Cancer: What is the Cost to Primary Care?
- 22/Dec/2008
Psychological Distress among Prostate Cancer Patients: Fact Or Fiction?
- 16/Dec/2008
Docetaxel as Salvage Therapy in Highly Pretreated and Drug Resistant Gastrointestinal Carcinomas
- 03/Dec/2008
Observational Study of Topical Imiquimod Immunotherapy in the Treatment of Difficult Lentigo Maligna
- 03/Dec/2008
Increased Incidence of Loco-Regional Recurrences Among African American Women with Terminal Stage Breast Cancer
- 03/Nov/2008
Nef as a Proliferative Factor for Kidney Epithelial Cells in HIV-Associated Nephropathy
- 30/Oct/2008
Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
- 25/Sep/2008
Serum Messenger RNA as a Biomarker and its Clinical Usefulness in Malignancies
- 22/Sep/2008
Integrated 18FDG PET/CT: Utility and Applications in Clinical Oncology
- 19/Sep/2008
Bone Marrow Micrometastases in Breast Cancer Patients: A Long-Term Follow-up Study
- 04/Sep/2008
Targeted Chemotherapy Using a Cytotoxic Somatostatin Conjugate to Inhibit Tumor Growth and Metastasis in Nude Mice
- 19/Aug/2008
A Phantom Study on Target Localization Accuracy Using Cone-Beam Computed Tomography
- 18/Aug/2008
Recurrent Respiratory Papillomatosis (RRP) - Juvenile Onset
- 18/Jul/2008
Case Report: Thymic Carcinoma Metastatic to Small Bowel
- 09/Jul/2008
Phase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the Prostate
- 08/Jul/2008
Exvivo Experiments of Human Ovarian Cancer Ascites-Derived Exosomes Presented by Dendritic Cells Derived from Umbilical Cord Blood for Immunotherapy Treatment
- 11/Jun/2008
B-Cell Lymphoma of the Mandible: A Case Report
- 11/Jun/2008
Documentation of Complete Response in Metastatic Breast Cancer to Liver and Bone Achieved with Trastuzumab and Pegylated Liposomal Doxorubicin
- 11/Jun/2008
Multicentric Adenocarcinomas in a Long-Segment of Barrett’s Esophagus
- 09/Jun/2008
Potential of Neural Stem Cells for the Treatment of Brain Tumors
- 09/Jun/2008
A Single Institution’s Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma
- 09/Jun/2008
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma – A Critical Review
- 21/May/2008
Experimental antioxidant therapy in ataxia telangiectasia
- 20/May/2008
Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma – A Critical Review
- 20/May/2008
The Presence of Precursors of Benign Pre-B Lymphoblasts (Hematogones) in the Bone Marrow of a Paediatric Patient with Cytomegalovirus Infection
- 20/May/2008
Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
- 19/May/2008
Effect of Thiazolidinediones on the Erythropoeitic and Germinal Cells in the Male Wistar Rats
- 19/May/2008
Octreotide in Palliative Treatment of Hepatic Metastases: Is it Effective for Clinical Stabilization?
- 13/May/2008
Multidisciplinary Approach in Managing Orbital Tumors in Ibadan, Nigeria
- 08/May/2008
Pancreas Cancer Survival in the Gemcitabine Era
- 29/Apr/2008
Therapeutic Anti-Tumor Vaccines: From Tumor Inhibition to Enhancement
- 29/Apr/2008
Should We Consider Cancers as Embryonic Diseases or as Consequences of Stem-Cell Deregulation?
- 29/Apr/2008
Primary Adrenal Leiomyosarcoma: a Case Report and Literature Review
- 28/Apr/2008
The ‘Pokemon’ (ZBTB7) Gene: No Evidence of Association with Sporadic Breast Cancer
- 28/Apr/2008
Phase II Study of S-1 Monotherapy as a First-line, Combination Therapy of S-1 plus Cisplatin as a Second-line, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma
- 28/Apr/2008
Adenocarcinoma Arising within a Colonic Diverticulum in a Patient with Recurrent Diverticulitis
- 24/Apr/2008
Octreotide in Palliative Treatment of Unresectable Cholangiocarcinoma: Is it Effective for Disease Stabilization?
- 24/Apr/2008
A Comparison of Clinicopathological Features and Molecular Markers in British and Nigerian Women with Breast Cancer
- 24/Apr/2008
Leptomeningeal Metastases in a Patient with an Extragonadal Germ Cell Tumor
- 24/Apr/2008
HSP70s: From Tumor Transformation to Cancer Therapy
- 24/Apr/2008
Response of Cutaneous Metastases from Breast Cancer to Capecitabine
- 18/Apr/2008
Unusual Malignant Transformation of Recurrent Sebaceoma. A Case Report
- 15/Apr/2008
A Hybrid Lesion of Lung Cancer and Aspergillosis
- 10/Apr/2008
Mitochondrial Defects in Breast Cancer
- 01/Apr/2008
Disruption of the Non-Canonical WNT Pathway in Lung Squamous Cell Carcinoma
- 01/Apr/2008
Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E
- 01/Apr/2008
Signal Transduction Involving the Dmp1 Transcription Factor and its Alteration in Human Cancer
- 01/Apr/2008
A Comparison of Merkel Cell Carcinoma and Melanoma: Results from the California Cancer Registry
- 01/Apr/2008
A Unique Complication Associated with Concurrent Chemoradiation for the Treatment of Locally Advanced Head and Neck Cancer
- 01/Apr/2008
The Relationship Between MR Demonstration of Extramural Venous Invasion and Nodal Disease in Rectal Cancer
- 01/Apr/2008
The Effect of Docetaxel (Taxotere®) on Human Gastric Cancer Cells Exhibiting Low-Dose Radiation Hypersensitivity
- 28/Mar/2008
Evaluation of Image Enhancement Method on Target Registration Using Cone Beam CT in Radiation Therapy
- 28/Mar/2008
Functional Activities and Immunohistochemical Cellular Distribution of Glutathione S-Transferases in Normal, Dysplastic, and Squamous Cell Carcinoma Human Oral Tissues
- 28/Mar/2008
Pre-operative Concomitant Radio-chemotherapy in Bulky Carcinoma of the Cervix: A Single Institution Study
- 27/Mar/2008
Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with Rituximab
- 27/Mar/2008
Signet-Ring Cell Carcinoma Arising in the Gastric Stump After Duodenopancreatectomy for Ductal Adenocarcinoma of the Pancreas: A Case Report
- 27/Mar/2008
Renal Cell Carcinoma with IVC Thrombi; Current Concepts and Future Perspectives
- 26/Mar/2008
Radionuclide Imaging of Apoptosis in Malignancies: Promise and Pitfalls of 99mTc-Hynic-rh-Annexin V Imaging
- 25/Mar/2008
Bead-Selected Antitumor Genetic Cell Vaccines
- 25/Mar/2008
Primary MALT Type Skin Lymphoma—Is ‘Wait and See’ a Possible Strategy?
- 19/Mar/2008
Molecular Determinants of Glioblastoma Response to Epidermal Growth Factor Receptor Kinase Inhibitors
- 19/Mar/2008
Successful Downstaging of High Rectal and Recto-Sigmoid Cancer by Neo-Adjuvant Chemo-Radiotherapy
- 01/Mar/2008
Malignant Struma Ovarii: Good Response after Thyroidectomy and 131I Ablation Therapy
- 29/Feb/2008
Long Survival in a Patient with Brain Metastases from Breast Cancer
- 09/Feb/2008
Acute Visual Loss Induced by Dexamethasone During Neoadjuvant Docetaxol
- 09/Feb/2008
Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy?
- 09/Feb/2008
Oxaliplatin for Metastatic Colon Cancer in a Patient with Renal Failure
- 09/Feb/2008
Primary Osteosarcoma of the Right Heart Ventricle and Atrium; a Case Report
- 09/Feb/2008
Atypical Fibroxanthoma
- 09/Feb/2008
Molecular Cloning and Functional Characterization of Mouse α3(IV)NC1
- 09/Feb/2008
Thyroid Carcinoma with Bone Metastases: A Prognostic Factor Study
- 09/Feb/2008
Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor Inactivation
- 09/Feb/2008
Recent Advances in Proteomics and Cancer Biomarker Discovery
- 09/Feb/2008
Expression Levels of Thymidylate Synthase, Thymidylate Phosphorylase and Dihydropyrimidine Dehydrogenase in Head and Neck Squamous Cell Carcinoma: Preliminary Study
- 22/Jan/2008
Biological Markers Predictive of Invasive Recurrence in DCIS
- 22/Jan/2008
Animal-Type Melanoma: A Rare Type of Malignant Melanoma with an Indolent Clinical Behaviour
- 22/Jan/2008
Palestinian Children in the Hemato-Oncology Ward of an Israeli Hospital
- 21/Jan/2008
Late Relapse and Follow-up Protocols in Testicular Germ Cell Tumours: The Edinburgh Cancer Centre Experience and Review of the Literature
- 21/Jan/2008
Long-Term Remission in a Case of Anaplastic Thyroid Carcinoma Following Local Irradiation and High-Dose Chemotherapy With Autologous Peripheral Blood Stem Cell Transplantation
- 13/Dec/2007
Successful Treatment of Osteosarcoma Arising in Osteogenesis Imperfecta with High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation Followed-by Limb Sparing Surgery
- 12/Dec/2007
Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study
- 11/Dec/2007
Colon Cancer and Physical Activity: A Content Analysis of Reciprocal Relationship
- 11/Dec/2007
Single Agent Irinotecan for The Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN)
- 11/Dec/2007
A Serious Complication of Allogeneic Stem Cell Transplantation: Relapsing Pseudomonas aeruginosa Panniculitis
- 11/Dec/2007
Treatment Approaches for Hepatocellular Carcinoma
- 11/Dec/2007
Oxaliplatin-Induced Haemolytic Anaemia: A Case Report
- 11/Dec/2007
Thoracic Sarcoidosis Mimicking Metastatic Testicular Cancer: Three Case Reports
- 11/Dec/2007